CERo Therapeutics Adds UC Davis as Site for Phase 1 CER-1236 Trial in Blood Cancers
Bitget2026/10/26 21:22- CERo Therapeutics activated UC Davis as a site for its ongoing Phase 1 CERTAIN-T trial of CER-1236 in blood cancers.
- UC Davis also manufactures CER-1236, potentially expanding recruitment capacity while shortening the time between manufacturing and patient infusion.
- Previously reported findings covered six patients; a June 2026 update showed no severe treatment-related adverse events during the initial safety assessment.
- Preliminary observations indicated clinical improvement in two patients, but formal assessments remain ongoing; definitive safety or efficacy conclusions cannot yet be drawn.
- The trial protocol now includes myelodysplastic syndromes and myelofibrosis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley's Latest View: Open-source models are not a nightmare for software companies; those vendors who control enterprise context and pricing power will prevail
The usage of open-weight artificial intelligence (AI) models continues to rise, and Morgan Stanley believes that companies such as CrowdStrike, Datadog, and Microsoft will benefit from this wave of industry growth.
South Korea's KOSPI surges over 4% intraday, triggering the sidecar mechanism
iPhone Duo debut encounters issues! Apple (AAPL.US) responds: Only affects a "small number" of devices, users can contact AppleCare for a free replacement
Apple's first foldable phone, the iPhone Duo, was reported to have internal screen line faults during its launch weekend. Apple stated that only a small number of devices are affected and promised replacements. iFixit suggested that hinge design could be the cause.
Crypto prices
More
